A year of follow-up makes the trajectory visible. See the lipid and metabolic changes, including the medication context needed to read the results fairly.
P.M., male, 43, had five blood panels over the April 2025 to April 2026 period. The source’s main comparison table shows April 2025, December 2025 and April 2026. Across the full year, ApoB fell from 126 to 82 mg/dL, HOMA-IR from 3.02 to 0.61 and KDM-13 from 45.9 to 33.3 years.
A timeline shows when the changes happened
P.M.’s ApoB did not move in a straight line, and the largest reported fall came late in the year. Keeping the intermediate readings and isotretinoin period beside the result gives the comparison more meaning than a single before-and-after number.
Starting point and context
The trajectory was not a straight line. ApoB was 123 mg/dL in December 2025 before reaching 82 in April 2026; HOMA-IR had already fallen to 1.91 by December. LDL fell from 188.7 to 124.7 mg/dL across the year. The repeated tests provide more context than a single before-and-after comparison, while still representing one person’s observational record.
Explore EVA blood biomarker testing
The recorded results
| Biomarker | Apr 2025 | Dec 2025 | Apr 2026 | Total Change |
|---|---|---|---|---|
| ApoB (mg/dL) | 126 | 123 | 82 | −35% |
| LDL (mg/dL) | 188.7 | 185.6 | 124.7 | −34% |
| Total Cholesterol (mg/dL) | 259 | 253 | 183 | −29% |
| Lp(a) (nmol/L) | 116.42 | 69.90 | 56.00 | −52% |
| Triglycerides (mg/dL) | 101 | 112 | 62 | −39% |
| HOMA-IR | 3.02 | 1.91 | 0.61 | −80% |
| KDM-13 Biological Age | 45.9 yrs | — | 33.3 yrs | −12.6 yrs |
Figures are reproduced from the case record, including qualitative entries and reported percentage changes. Source labels such as optimal describe the case’s interpretation, not a universal reference range. A dash indicates a value not supplied.
Context that matters
- P.M. used isotretinoin for resistant inflammatory back acne from approximately October 2025 to March 2026 and had discontinued it by the account’s follow-up. This medication period is relevant to interpretation, particularly the lipid results and the Lp(a) change.
- Lp(a) fell from 116.42 to 56.00 nmol/L, a source-reported 52% reduction. It cannot be attributed independently to the supplement protocol from this record; the original planned to reassess at the next draw.
- The source’s chart also includes ApoB 95 mg/dL in July 2025 and labels that panel non-fasting. The fasting-status qualifier is retained; this page does not assume it explains the ApoB value.
- Five panels are reported, but a complete five-panel numerical table is not supplied. Missing dates and values have not been invented.
- The detailed KDM-13 result is 45.9 to 33.3 years, a 12.6-year reduction. The shared source summary’s isolated 6.3-year subtitle does not match those values and is not used as this page’s result.
The recorded protocol
The source does not supply a complete supplement list or dosing schedule for this case. The named interventions and relevant clinical context are described above and below.
Learn about personalised supplements
What remained in progress
ApoB at 82 mg/dL was close to the source’s stated target below 80 mg/dL. Further testing was planned to clarify the lipid trajectory after isotretinoin. A reduction seen during a mixed lifestyle, supplement and medication history cannot establish the contribution of any one element.
Reading the biological-age result
Biological-age scores are model outputs derived from the inputs available to that model. A lower score is not a measured gain in lifespan. Different models use different inputs and should be labelled and interpreted separately.
Why does the medication history appear beside the results?
Isotretinoin was used during part of the follow-up period and can affect lipid interpretation. Keeping that context visible helps readers avoid attributing every change to the supplement protocol.
How this connects to EVA
EVA connects blood testing, clinician-reviewed personalised supplements and follow-up. Blood Intelligence uses your blood results; Elite DNA + Blood adds genetic information. DNA is optional. The aim is a personal plan grounded in your information, with review as new results become available.
Start a record you can learn from over time
If you want to track progress rather than rely on a one-off result, begin with a baseline that can support later comparison and review.
See how to start with EVAExplore blood testing, optional DNA and personalised supplements, with the current steps to get started in Dubai.
This is an individual observational case, not a controlled trial. Biomarker changes and biological-age scores do not establish the effect of a particular supplement, predict an individual’s lifespan or guarantee future results. The protocol described was personalised and is not a recommendation to self-prescribe. EVA supports informed health decisions and is not intended to diagnose, treat, cure or prevent disease. Consult a qualified healthcare provider for medical advice.
Source: EVA clinical case record supplied for publication. Observation dates and model names are shown in the case. Prepared for web publication in October 2026.